Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tominersen Open-Label Extension in Huntington's Disease
NCT03842969Phase 3Completed
- Sponsor
- Roche
- Start
- Apr 2019
- Primary completion
- Mar 2022
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 8
01
Overview
A Phase 3 trial of tominersen in Huntington's disease (HD), sponsored by Roche. Started Apr 2019; status: completed.
02
Drugs
tominersen
03
Conditions
Huntington's disease (HD)
Beyond the preview
Go deeper on NCT03842969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03842969.